CN102421799A - 用于高分子脂联素分析的新型单克隆抗体及其应用 - Google Patents
用于高分子脂联素分析的新型单克隆抗体及其应用 Download PDFInfo
- Publication number
- CN102421799A CN102421799A CN2010800200262A CN201080020026A CN102421799A CN 102421799 A CN102421799 A CN 102421799A CN 2010800200262 A CN2010800200262 A CN 2010800200262A CN 201080020026 A CN201080020026 A CN 201080020026A CN 102421799 A CN102421799 A CN 102421799A
- Authority
- CN
- China
- Prior art keywords
- adiponectin
- hmw
- monoclonal antibody
- latex
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000011690 Adiponectin Human genes 0.000 title claims abstract description 172
- 108010076365 Adiponectin Proteins 0.000 title claims abstract description 172
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 57
- 239000000427 antigen Substances 0.000 claims abstract description 14
- 102000036639 antigens Human genes 0.000 claims abstract description 14
- 108091007433 antigens Proteins 0.000 claims abstract description 14
- 239000004816 latex Substances 0.000 claims description 65
- 229920000126 latex Polymers 0.000 claims description 65
- 229920000642 polymer Polymers 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 37
- 238000004458 analytical method Methods 0.000 claims description 32
- 239000002245 particle Substances 0.000 claims description 26
- 230000004520 agglutination Effects 0.000 claims description 9
- 230000001900 immune effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000009260 cross reactivity Effects 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 description 32
- 239000008280 blood Substances 0.000 description 32
- 239000012530 fluid Substances 0.000 description 24
- 238000013016 damping Methods 0.000 description 22
- 210000002966 serum Anatomy 0.000 description 20
- 238000002965 ELISA Methods 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 17
- 238000002523 gelfiltration Methods 0.000 description 16
- 206010070834 Sensitisation Diseases 0.000 description 15
- 230000008313 sensitization Effects 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- 239000013060 biological fluid Substances 0.000 description 13
- 239000007788 liquid Substances 0.000 description 12
- 238000003118 sandwich ELISA Methods 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 239000007983 Tris buffer Substances 0.000 description 9
- 229940098773 bovine serum albumin Drugs 0.000 description 9
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000002203 pretreatment Methods 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 101000775469 Homo sapiens Adiponectin Proteins 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 102000057799 human ADIPOQ Human genes 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 238000012092 latex agglutination test Methods 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 4
- 102000008857 Ferritin Human genes 0.000 description 4
- 238000008416 Ferritin Methods 0.000 description 4
- 108050000784 Ferritin Proteins 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 238000001641 gel filtration chromatography Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000012797 qualification Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 2
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- 102000009843 Thyroglobulin Human genes 0.000 description 2
- 108010034949 Thyroglobulin Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000010324 immunological assay Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229960002175 thyroglobulin Drugs 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000006173 Good's buffer Substances 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000002546 agglutinic effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000003746 solid phase reaction Methods 0.000 description 1
- 238000010671 solid-state reaction Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (6)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009112624 | 2009-05-07 | ||
JP2009-112624 | 2009-05-07 | ||
PCT/JP2010/057747 WO2010128657A1 (ja) | 2009-05-07 | 2010-05-06 | 高分子アディポネクチン分析のための新規モノクローナル抗体とその利用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102421799A true CN102421799A (zh) | 2012-04-18 |
CN102421799B CN102421799B (zh) | 2015-02-18 |
Family
ID=43050155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201080020026.2A Active CN102421799B (zh) | 2009-05-07 | 2010-05-06 | 用于高分子脂联素分析的新型单克隆抗体及其应用 |
Country Status (9)
Country | Link |
---|---|
US (2) | US8871518B2 (zh) |
EP (1) | EP2431391B1 (zh) |
JP (1) | JP5824359B2 (zh) |
KR (1) | KR20120016117A (zh) |
CN (1) | CN102421799B (zh) |
AU (1) | AU2010245543B2 (zh) |
CA (1) | CA2760980A1 (zh) |
ES (1) | ES2560559T3 (zh) |
WO (1) | WO2010128657A1 (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104673755A (zh) * | 2014-11-06 | 2015-06-03 | 中国医学科学院北京协和医院 | 抗人高分子脂联素的单克隆抗体及其应用 |
CN104694478A (zh) * | 2014-11-06 | 2015-06-10 | 中国医学科学院北京协和医院 | 抗人脂联素的单克隆抗体及其应用 |
CN108700576A (zh) * | 2017-01-20 | 2018-10-23 | 深圳市新产业生物医学工程股份有限公司 | 制备抗体对的方法、试剂盒及试剂盒的应用和制备抗体对的系统 |
CN111337692A (zh) * | 2020-03-25 | 2020-06-26 | 江西乐成生物医疗有限公司 | 一种脂联素测定试剂及制备方法 |
CN111896742A (zh) * | 2015-07-07 | 2020-11-06 | 思齐乐 | 流感效力试验 |
CN114295840A (zh) * | 2021-12-29 | 2022-04-08 | 中元汇吉生物技术股份有限公司 | 一种高灵敏度定量测定脂联素的试剂盒及其制备方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103777023B (zh) * | 2013-12-16 | 2015-04-08 | 深圳市安之酶生物技术有限公司 | 纳米胶乳增强免疫比浊法测定脂联素的试剂盒 |
JP6554806B2 (ja) * | 2015-02-05 | 2019-08-07 | 富士ゼロックス株式会社 | 導電性部材、帯電装置、プロセスカートリッジ、画像形成装置、および導電性部材の製造方法 |
CN110372783A (zh) * | 2019-04-15 | 2019-10-25 | 杭州博谱医药科技有限公司 | 一种脂联素抗原、抗体及其胶乳试剂的制备方法以及脂联素检测试剂盒 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004086040A1 (ja) * | 2003-03-24 | 2004-10-07 | Mitsubishi Kagaku Iatron, Inc. | アディポネクチン分析用ラテックス試薬及びアディポネクチン分析方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60239622D1 (de) | 2001-08-17 | 2011-05-12 | Fujirebio Kk | Verfahren zur diagnose oder überwachung eines fehlers im zuckerstoffwechsel |
CN1867828B (zh) | 2003-10-15 | 2010-09-29 | 第一化学药品株式会社 | 脂连蛋白多聚体的分离测定方法 |
JP5380303B2 (ja) * | 2007-12-14 | 2014-01-08 | 大塚製薬株式会社 | 高分子アディポネクチン測定法 |
-
2010
- 2010-05-06 JP JP2011512352A patent/JP5824359B2/ja active Active
- 2010-05-06 AU AU2010245543A patent/AU2010245543B2/en not_active Ceased
- 2010-05-06 EP EP10772175.5A patent/EP2431391B1/en active Active
- 2010-05-06 CA CA2760980A patent/CA2760980A1/en not_active Abandoned
- 2010-05-06 KR KR1020117028624A patent/KR20120016117A/ko not_active Application Discontinuation
- 2010-05-06 ES ES10772175.5T patent/ES2560559T3/es active Active
- 2010-05-06 CN CN201080020026.2A patent/CN102421799B/zh active Active
- 2010-05-06 US US13/319,054 patent/US8871518B2/en active Active
- 2010-05-06 WO PCT/JP2010/057747 patent/WO2010128657A1/ja active Application Filing
-
2014
- 2014-10-07 US US14/508,993 patent/US9933442B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004086040A1 (ja) * | 2003-03-24 | 2004-10-07 | Mitsubishi Kagaku Iatron, Inc. | アディポネクチン分析用ラテックス試薬及びアディポネクチン分析方法 |
Non-Patent Citations (3)
Title |
---|
AYAKO NISHIMURA等: "Determination of adiponectin in serum using a latex particle-enhanced turbidimetric immunoassay with an automated analyzer", 《CLINICA CHIMICA ACTA》 * |
TOSHIMI TANITA等: "Performance of ELISA for specific measurement of High-Molecular-Weight (HMW) adiponectin", 《JOURNAL OF IMMUNOLOGICAL METHODS》 * |
YASUKO NAKANO等: "A novel enzyme-linked immunosorbent assay specific for high-molecular-weight adiponectin", 《JOURNAL OF LIPID RESEARCH》 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104673755A (zh) * | 2014-11-06 | 2015-06-03 | 中国医学科学院北京协和医院 | 抗人高分子脂联素的单克隆抗体及其应用 |
CN104694478A (zh) * | 2014-11-06 | 2015-06-10 | 中国医学科学院北京协和医院 | 抗人脂联素的单克隆抗体及其应用 |
CN104694478B (zh) * | 2014-11-06 | 2018-06-26 | 中国医学科学院北京协和医院 | 抗人脂联素的单克隆抗体及其应用 |
CN111896742A (zh) * | 2015-07-07 | 2020-11-06 | 思齐乐 | 流感效力试验 |
CN108700576A (zh) * | 2017-01-20 | 2018-10-23 | 深圳市新产业生物医学工程股份有限公司 | 制备抗体对的方法、试剂盒及试剂盒的应用和制备抗体对的系统 |
CN111337692A (zh) * | 2020-03-25 | 2020-06-26 | 江西乐成生物医疗有限公司 | 一种脂联素测定试剂及制备方法 |
CN111337692B (zh) * | 2020-03-25 | 2023-10-03 | 江西乐成生物医疗有限公司 | 一种脂联素测定试剂及制备方法 |
CN114295840A (zh) * | 2021-12-29 | 2022-04-08 | 中元汇吉生物技术股份有限公司 | 一种高灵敏度定量测定脂联素的试剂盒及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2010245543A1 (en) | 2011-12-01 |
AU2010245543B2 (en) | 2015-08-13 |
KR20120016117A (ko) | 2012-02-22 |
EP2431391A1 (en) | 2012-03-21 |
EP2431391B1 (en) | 2015-12-02 |
US20120052596A1 (en) | 2012-03-01 |
WO2010128657A1 (ja) | 2010-11-11 |
EP2431391A4 (en) | 2013-03-27 |
ES2560559T3 (es) | 2016-02-19 |
US20150025226A1 (en) | 2015-01-22 |
CN102421799B (zh) | 2015-02-18 |
CA2760980A1 (en) | 2010-11-11 |
JPWO2010128657A1 (ja) | 2012-11-01 |
US9933442B2 (en) | 2018-04-03 |
US8871518B2 (en) | 2014-10-28 |
JP5824359B2 (ja) | 2015-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102421799A (zh) | 用于高分子脂联素分析的新型单克隆抗体及其应用 | |
Grauballe et al. | Optimized enzyme‐linked immunosorbent assay for detection of human and bovine rotavirus in stools: Comparison with electron‐microscopy, immunoelectro‐osmophoresis, and fluorescent antibody techniques | |
JPH05264553A (ja) | ヘリコバクターピロリ検出用の抗原調製物 | |
CN107102135A (zh) | 用于减少非特异性结合的免疫检验方法和试剂 | |
CN105588944B (zh) | 检测agp1、serpina3和cdh1含量的系统在筛查活动性结核病患者中的应用 | |
US20210011037A1 (en) | Lateral flow immunoassays for the detection of antibodies against biological drugs | |
EP2357199A1 (en) | Antibody against n-terminal region of -chain of hemoglobin | |
EP2414843A1 (en) | Detection of fibrin and fibrinogen degradation products and associated methods of production and use for the detection and monitoring of cancer | |
NO177444B (no) | Fremgangsmåte for immunometrisk bestemmelse av et antigen, samt utstyrspakke for slik bestemmelse | |
CN110361547A (zh) | 一种化学发光定量检测粪便潜血的试剂及其检测方法和其在检测下消化道健康的用途 | |
CN107255711B (zh) | 骨桥蛋白用于制备或筛选慢加急性肝衰竭诊断试剂的用途 | |
JP2008175814A (ja) | 尿中タンパク質分子の検出・定量による糖尿病性腎症の検査方法及びそれに使用するキット | |
JPH01503331A (ja) | モノカインの検査法 | |
CA2344589A1 (en) | Diagnostic assays for detection of giardia lamblia | |
KR101486548B1 (ko) | 나이관련 황반변성 진단용 마커 및 이를 이용한 나이 관련 황반 변성 진단 방법 | |
US6844163B1 (en) | Method for analyzing the amount of intraabdominal adipose tissue | |
KR102525734B1 (ko) | 데옥시하이푸신·신타제 유전자를 지표로서 사용하는 동맥 경화 및 암의 검출 방법 | |
JPH0580053A (ja) | ヒト子宮体癌細胞の免疫化学的検出方法 | |
KR102031845B1 (ko) | 신규한 면역글로불린 e의 에피토프, 그와 결합하는 항체 및 상기 항체를 포함하는 시료 중 면역글로불린 e를 분석하기 위한 키트 | |
CN108459165B (zh) | Orai1蛋白作为心肌梗塞生物标志物的用途 | |
CN104673755A (zh) | 抗人高分子脂联素的单克隆抗体及其应用 | |
CN117783526A (zh) | 一种定量检测生物体液中热带念珠菌烯醇化酶的方法 | |
RU2291437C2 (ru) | Способ мониторинга за состоянием больных сахарным диабетом и развитием неврологических и сосудистых его осложнений | |
JP6558568B2 (ja) | 細菌由来成分の免疫学的検出方法 | |
CN116539894A (zh) | Capg在制备病理性心肌肥厚检测试剂中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: Tokyo, Japan Applicant after: LSI MEDIENCE Corp. Applicant after: OTSUKA PHARMACEUTICAL Co.,Ltd. Address before: Tokyo, Japan Applicant before: Mitsubishi Chemical Medience Corp. Applicant before: OTSUKA PHARMACEUTICAL Co.,Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: MITSUBISHI CHEMICAL SAFETY INSTITUTE LTD. TO: MEIDI ENSI LIFE TECHNOLOGY CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170417 Address after: Tokyo, Japan Patentee after: LSI MEDIENCE Corp. Address before: Tokyo, Japan Co-patentee before: OTSUKA PHARMACEUTICAL Co.,Ltd. Patentee before: LSI MEDIENCE Corp. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240311 Address after: Ehime Prefecture, Japan Patentee after: Pu Heji Country or region after: Japan Address before: Tokyo, Japan Patentee before: LSI MEDIENCE Corp. Country or region before: Japan |
|
TR01 | Transfer of patent right |